SCHEDULE: Foresite Capital Discloses Significant Stake in Latigo Biotherapeutics

Foresite Capital entities and James B. Tananbaum have collectively reported beneficial ownership of 14.5% of Latigo Biotherapeutics, Inc. common stock following the company's IPO.

Summary

• Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC, Foresite Capital Fund V, L.P., Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC, and James B. Tananbaum (collectively, the 'Reporting Persons') have filed a Schedule 13D.
• The filing discloses beneficial ownership of 9,181,328 shares of Latigo Biotherapeutics, Inc. common stock, representing 14.5% of the outstanding shares.
• This ownership is a result of various investments in Series A-2 and Series B Convertible Preferred Stock, a convertible promissory note, and a direct purchase of common stock in the company's Initial Public Offering (IPO).
• The Reporting Persons hold these securities for investment purposes and may adjust their holdings based on market conditions and the company's performance.
• The IPO occurred on August 10, 2026, with the prospectus filed on August 7, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting significant investment and strategic positioning by Foresite Capital in Latigo Biotherapeutics, Inc. following its IPO.

Positives

• Significant investment by Foresite Capital entities in Latigo Biotherapeutics, Inc., indicating confidence in the company's prospects.
• Collective beneficial ownership of 14.5% of the company's common stock by the Reporting Persons.
• Active participation in the company's Initial Public Offering (IPO) through direct purchase of shares.
• Diversified investment strategy including preferred stock, convertible notes, and common stock.

Negatives

• The filing does not detail any negative financial performance or operational issues of Latigo Biotherapeutics, Inc. itself, as it is a Schedule 13D focused on beneficial ownership.
• Potential for future stock sales by the Reporting Persons could impact share price, though this is a standard disclosure for investment entities.

Risks

• Future stock sales by the Reporting Persons could impact the market price of Latigo Biotherapeutics, Inc. common stock.
• The investment strategy of the Reporting Persons is subject to market conditions, company performance, and alternative investment opportunities, which could lead to changes in their holdings.

Future Outlook

The Reporting Persons state that they hold their securities for investment purposes and may, from time to time, acquire additional shares, retain or sell existing shares, or distribute shares to their members or limited partners. Their future actions will depend on factors such as stock price, market conditions, and the Issuer's business performance.

Management Comments

• The principal occupation of each of the Reporting Persons is the venture capital investment business.
• Tananbaum may be deemed to have sole power to vote and dispose of shares directly owned by Fund VI, Fund V, and Opportunity Fund V.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing by Foresite Capital, a prominent venture capital firm, highlights significant post-IPO investment activity. Such filings are common as institutional investors establish or adjust their positions following a company's public debut, indicating a level of strategic interest beyond passive investment.

Stakeholder Impact

• Shareholders: Potential for increased market activity and price fluctuations due to Foresite Capital's investment and potential future trading activities.
• Company Management: The significant stake held by Foresite Capital may influence strategic decisions and board composition, given James B. Tananbaum's role as a director.

Next Steps

• The Reporting Persons may acquire additional shares of Common Stock.
• The Reporting Persons may retain and/or sell all or a portion of the Common Stock held.
• The Reporting Persons may distribute the Common Stock held to their respective members or limited partners.

Key Dates

Recommendation

The filing indicates a significant investment by a sophisticated venture capital firm, suggesting a belief in the company's long-term potential. However, as this is a Schedule 13D focused on ownership rather than operational or financial results, a 'hold' recommendation is prudent, pending further information on the company's performance and Foresite's specific intentions.

Keywords

Latigo Biotherapeutics, Foresite Capital, Schedule 13D, Beneficial Ownership, IPO, Venture Capital, Investment, Common Stock